ERAS vs BLTE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ERAS · Erasca$13.61 ▼ 4.29%
BLTE · Belite Bio$127.38 ▼ 15.65%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ERAS +370.9%
- BLTE -6.3%
Head to head
| Metric | ERAS | BLTE |
|---|---|---|
| Price | $13.61 | $127.38 |
| Change today | ▼ 4.29% | ▼ 15.65% |
| Market cap | $4.78B | $5.17B |
| Return, 3 months | -22.7% | -19.8% |
| Return, year to date | +265.9% | -20.4% |
| Return, 1 year | +366.1% | +5.7% |
| P/E (TTM) | – | – |
| P/B | 5.2 | 6.7 |
| P/E percentile vs own 5y | 12th | 40th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -67.7% | -39.6% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -48.7% | -21.2% |
| Analyst target vs. price | +81.3% | +81.9% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 43 | 32 |
| 30-day volatility | 81.2% | 74.4% |
| Max drawdown, 1 year | -59.5% | -34.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BLTE is the largest of the group by market value.
- ERAS has returned the most over the past year.
- BLTE has been the calmest stock over the last 30 days.